Tiotropium bromide

    WARNING: This product is for research use only, not for human or veterinary use.

MedKoo CAT#: 318877

CAS#: 136310-93-5

Description: Tiotropium bromide is a long-acting, 24-hour, anticholinergic bronchodilator used in the management of chronic obstructive pulmonary disease (COPD). Tiotropium is a muscarinic receptor antagonist, often referred to as an antimuscarinic or anticholinergic agent. Although it does not display selectivity for specific muscarinic receptors, when topically applied it acts mainly on M3 muscarinic receptors[7] located on smooth muscle cells and submucosal glands. This leads to a reduction in smooth muscle contraction and mucus secretion and thus produces a bronchodilatory effect.


Chemical Structure

img
Tiotropium bromide
CAS# 136310-93-5

Theoretical Analysis

MedKoo Cat#: 318877
Name: Tiotropium bromide
CAS#: 136310-93-5
Chemical Formula: C19H22BrNO4S2
Exact Mass:
Molecular Weight: 472.412
Elemental Analysis: C, 48.31; H, 4.69; Br, 16.91; N, 2.96; O, 13.55; S, 13.57

Price and Availability

This product is not in stock, which may be available by custom synthesis. For cost-effective reason, minimum order is 1g (price is usually high, lead time is 2~3 months, depending on the technical challenge). Quote less than 1g will not be provided. To request quote, please email to sales @medkoo.com or click below button.
Note: Price will be listed if it is available in the future.

Request quote for custom synthesis

Synonym: PUR-0200; PUR0200; PUR 0200; BA 679BR; BA-679BR; BA679BR; Tiotropium bromide, brand name: Spiriva.

IUPAC/Chemical Name: (1R,2R,4S,5S,7s)-7-(2-hydroxy-2,2-di(thiophen-2-yl)acetoxy)-9,9-dimethyl-3-oxa-9-azatricyclo[3.3.1.02,4]nonan-9-ium bromide

InChi Key: DQHNAVOVODVIMG-RGECMCKFSA-M

InChi Code: InChI=1S/C19H22NO4S2.BrH/c1-20(2)12-9-11(10-13(20)17-16(12)24-17)23-18(21)19(22,14-5-3-7-25-14)15-6-4-8-26-15;/h3-8,11-13,16-17,22H,9-10H2,1-2H3;1H/q+1;/p-1/t11?,12-,13+,16-,17+;

SMILES Code: C[N+]1([C@@H]2CC(C[C@H]1[C@H]3[C@@H]2O3)OC(=O)C(C4=CC=CS4)(C5=CC=CS5)O)C.[Br-]

Appearance: Solid powder

Purity: >98% (or refer to the Certificate of Analysis)

Shipping Condition: Shipped under ambient temperature as non-hazardous chemical. This product is stable enough for a few weeks during ordinary shipping and time spent in Customs.

Storage Condition: Dry, dark and at 0 - 4 C for short term (days to weeks) or -20 C for long term (months to years).

Solubility: Soluble in DMSO, not in water

Shelf Life: >2 years if stored properly

Drug Formulation: This drug may be formulated in DMSO

Stock Solution Storage: 0 - 4 C for short term (days to weeks), or -20 C for long term (months).

HS Tariff Code: 2934.99.9001

Preparing Stock Solutions

The following data is based on the product molecular weight 472.412 Batch specific molecular weights may vary from batch to batch due to the degree of hydration, which will affect the solvent volumes required to prepare stock solutions.

Recalculate based on batch purity %
Concentration / Solvent Volume / Mass 1 mg 5 mg 10 mg
1 mM 1.15 mL 5.76 mL 11.51 mL
5 mM 0.23 mL 1.15 mL 2.3 mL
10 mM 0.12 mL 0.58 mL 1.15 mL
50 mM 0.02 mL 0.12 mL 0.23 mL

Molarity Calculator

Calculate the mass, volume, or concentration required for a solution.
=
x
x
g/mol

*When preparing stock solutions always use the batch-specific molecular weight of the product found on the vial label and SDS / CoA (available online).

Reconstitution Calculator

The reconstitution calculator allows you to quickly calculate the volume of a reagent to reconstitute your vial. Simply enter the mass of reagent and the target concentration and the calculator will determine the rest.

=
÷

Dilution Calculator

Calculate the dilution required to prepare a stock solution.
x
=
x

1: Ramadan WH, Kabbara WK, El Khoury GM, Al Assir SA. Combined bronchodilators (tiotropium plus olodaterol) for patients with chronic obstructive pulmonary disease. Int J Chron Obstruct Pulmon Dis. 2015 Oct 30;10:2347-56. doi: 10.2147/COPD.S88246. eCollection 2015. Review. PubMed PMID: 26586940; PubMed Central PMCID: PMC4634833.

2: Pelaia G, Vatrella A, Busceti MT, Gallelli L, Calabrese C, Terracciano R, Lombardo N, Maselli R. Pharmacologic rationale underlying the therapeutic effects of tiotropium/olodaterol in COPD. Ther Clin Risk Manag. 2015 Oct 8;11:1563-72. doi: 10.2147/TCRM.S84151. eCollection 2015. Review. PubMed PMID: 26504398; PubMed Central PMCID: PMC4603718.

3: Alvarado-Gonzalez A, Arce I. Tiotropium Bromide in Chronic Obstructive Pulmonary Disease and Bronchial Asthma. J Clin Med Res. 2015 Nov;7(11):831-9. doi: 10.14740/jocmr2305w. Epub 2015 Sep 25. Review. PubMed PMID: 26491494; PubMed Central PMCID: PMC4596263.

4: Farne HA, Cates CJ. Long-acting beta2-agonist in addition to tiotropium versus either tiotropium or long-acting beta2-agonist alone for chronic obstructive pulmonary disease. Cochrane Database Syst Rev. 2015 Oct 22;10:CD008989. doi: 10.1002/14651858.CD008989.pub3. Review. PubMed PMID: 26490945.

5: Cheyne L, Irvin-Sellers MJ, White J. Tiotropium versus ipratropium bromide for chronic obstructive pulmonary disease. Cochrane Database Syst Rev. 2015 Sep 22;9:CD009552. doi: 10.1002/14651858.CD009552.pub3. Review. PubMed PMID: 26391969.

6: Muruganandan S, Jayaram L. Profile of a fixed-dose combination of tiotropium/olodaterol and its potential in the treatment of COPD. Int J Chron Obstruct Pulmon Dis. 2015 Jun 18;10:1179-89. doi: 10.2147/COPD.S54154. eCollection 2015. Review. PubMed PMID: 26124657; PubMed Central PMCID: PMC4476436.

7: Mihălţan F, Ulmeanu R. [Tiotropium in asthma--a new opportunity?]. Pneumologia. 2014 Oct-Dec;63(4):200-2. Review. Romanian. PubMed PMID: 25665363.

8: Rodrigo GJ, Castro-Rodríguez JA. What is the role of tiotropium in asthma?: a systematic review with meta-analysis. Chest. 2015 Feb;147(2):388-96. doi: 10.1378/chest.14-1698. Review. PubMed PMID: 25322075.

9: Keating GM. Tiotropium Respimat(®) Soft Mist™ inhaler: a review of its use in chronic obstructive pulmonary disease. Drugs. 2014 Oct;74(15):1801-16. doi: 10.1007/s40265-014-0307-4. Review. PubMed PMID: 25300412.

10: Karner C, Chong J, Poole P. Tiotropium versus placebo for chronic obstructive pulmonary disease. Cochrane Database Syst Rev. 2014 Jul 21;7:CD009285. doi: 10.1002/14651858.CD009285.pub3. Review. PubMed PMID: 25046211.

11: Rashid Q, Klein R. Tiotropium in the treatment of patients with asthma. South Med J. 2014 May;107(5):330-7. doi: 10.1097/SMJ.0000000000000108. Review. PubMed PMID: 24937736.

12: Mathioudakis AG, Chatzimavridou-Grigoriadou V, Evangelopoulou E, Mathioudakis GA, Siafakas NM. Comparative mortality risk of tiotropium administered via handihaler or respimat in COPD patients: are they equivalent? Pulm Pharmacol Ther. 2014 Aug;28(2):91-7. doi: 10.1016/j.pupt.2014.04.009. Epub 2014 May 16. Review. PubMed PMID: 24846455.

13: Institute for Quality and Efficiency in Health Care: Executive Summaries [Internet]. Cologne, Germany: Institute for Quality and Efficiency in Health Care (IQWiG); 2005-. Available from http://www.ncbi.nlm.nih.gov/books/NBK198783/ PubMed PMID: 24783293.

14: Novelli F, Costa F, Latorre M, Malagrinò L, Celi A, Vagaggini B, Paggiaro P. Tiotropium: a new therapeutic option in asthma. Monaldi Arch Chest Dis. 2013 Sep-Dec;79(3-4):109-15. Review. PubMed PMID: 24761528.

15: Befekadu E, Onofrei C, Colice GL. Tiotropium in asthma: a systematic review. J Asthma Allergy. 2014 Feb 27;7:11-21. doi: 10.2147/JAA.S38841. eCollection 2014. Review. PubMed PMID: 24600237; PubMed Central PMCID: PMC3942115.

16: Koblížek V. [The position of tiotropium in new treatment guidelines for chronic obstructive pulmonary disease]. Vnitr Lek. 2013 Dec;59(12):1073-80. Review. Czech. PubMed PMID: 24350939.

17: Tian JW, Chen JW, Chen R, Chen X. Tiotropium versus placebo for inadequately controlled asthma: a meta-analysis. Respir Care. 2014 May;59(5):654-66. doi: 10.4187/respcare.02703. Epub 2013 Oct 29. Review. PubMed PMID: 24170916.

18: Karabis A, Lindner L, Mocarski M, Huisman E, Greening A. Comparative efficacy of aclidinium versus glycopyrronium and tiotropium, as maintenance treatment of moderate to severe COPD patients: a systematic review and network meta-analysis. Int J Chron Obstruct Pulmon Dis. 2013;8:405-23. doi: 10.2147/COPD.S48967. Epub 2013 Sep 9. Review. PubMed PMID: 24043936; PubMed Central PMCID: PMC3772873.

19: Cheyne L, Irvin-Sellers MJ, White J. Tiotropium versus ipratropium bromide for chronic obstructive pulmonary disease. Cochrane Database Syst Rev. 2013 Sep 16;9:CD009552. doi: 10.1002/14651858.CD009552.pub2. Review. Update in: Cochrane Database Syst Rev. 2015;9:CD009552. PubMed PMID: 24043433.

20: Welsh EJ, Cates CJ, Poole P. Combination inhaled steroid and long-acting beta2-agonist versus tiotropium for chronic obstructive pulmonary disease. Cochrane Database Syst Rev. 2013 May 31;5:CD007891. doi: 10.1002/14651858.CD007891.pub3. Review. PubMed PMID: 23728670.